Japan · Delayed Price · Currency is JPY Kringle Pharma Statistics
Total Valuation
Kringle Pharma has a market cap or net worth of JPY 3.73 billion. The enterprise value is 2.66 billion.
| Market Cap | 3.73B |
| Enterprise Value | 2.66B |
Important Dates
The last earnings date was Monday, August 10, 2026.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kringle Pharma has 8.38 million shares outstanding. The number of shares has increased by 7.53% in one year.
| Current Share Class | 8.38M |
| Shares Outstanding | 8.38M |
| Shares Change (YoY) | +7.53% |
| Shares Change (QoQ) | +8.82% |
| Owned by Insiders (%) | 6.32% |
| Owned by Institutions (%) | 6.03% |
| Float | 6.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.90 |
| PB Ratio | 2.98 |
| P/TBV Ratio | 2.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.17
| Current Ratio | 17.17 |
| Quick Ratio | 9.74 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -61.23% and return on invested capital (ROIC) is -38.10%.
| Return on Equity (ROE) | -61.23% |
| Return on Assets (ROA) | -24.51% |
| Return on Invested Capital (ROIC) | -38.10% |
| Return on Capital Employed (ROCE) | -42.75% |
| Weighted Average Cost of Capital (WACC) | 6.48% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 17 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.33 |
Taxes
In the past 12 months, Kringle Pharma has paid 1.77 million in taxes.
| Income Tax | 1.77M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -9.28% in the last 52 weeks. The beta is 0.41, so Kringle Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | -9.28% |
| 50-Day Moving Average | 350.24 |
| 200-Day Moving Average | 393.59 |
| Relative Strength Index (RSI) | 68.00 |
| Average Volume (20 Days) | 157,440 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kringle Pharma had revenue of JPY 342.21 million and -808.44 million in losses. Loss per share was -110.24.
| Revenue | 342.21M |
| Gross Profit | 271.82M |
| Operating Income | -804.88M |
| Pretax Income | -806.68M |
| Net Income | -808.44M |
| EBITDA | n/a |
| EBIT | -804.88M |
| Loss Per Share | -110.24 |
Balance Sheet
The company has 1.07 billion in cash and no debt, with a net cash position of 1.07 billion or 127.37 per share.
| Cash & Cash Equivalents | 1.07B |
| Total Debt | n/a |
| Net Cash | 1.07B |
| Net Cash Per Share | 127.37 |
| Equity (Book Value) | 1.25B |
| Book Value Per Share | 149.38 |
| Working Capital | 1.84B |
Cash Flow
| Operating Cash Flow | -520.00M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 79.43%, with operating and profit margins of -235.20% and -236.24%.
| Gross Margin | 79.43% |
| Operating Margin | -235.20% |
| Pretax Margin | -235.73% |
| Profit Margin | -236.24% |
| EBITDA Margin | n/a |
| EBIT Margin | -235.20% |
| FCF Margin | n/a |
Dividends & Yields
Kringle Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.53% |
| Shareholder Yield | -7.53% |
| Earnings Yield | -21.67% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kringle Pharma has an Altman Z-Score of 0.89 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.89 |
| Piotroski F-Score | 2 |